(C4N2H7)6(C4N2H6)2V10O28 Decavanadate Compound: Synthesis, Chemical Characterization, and Assessment of Antitumor Potential

Abstract

Numerous investigations conducted over the last decade highlighted the antitumor properties of decavanadate compounds. In this study, we synthesized and characterized a novel decavanadate compound of a formula unit (C4N2H7)6(C4N2H6)2V10O28. Its structural characterisation performed by single-crystal X-ray diffraction revealed that the compound crystallized in the monoclinic system space group P21/c with lattice parameters a = 11.937(8) Å, b = 13.399(6) Å, c = 17.941(3) Å, β = 105.35(3)°, Z = 4 and V = 2767.4(9) Å3. In the crystal, the centrosymetric decavanadate groups [V10O28]6– and the organic cations 2-methylimidazolium participated in O–H…N hydrogen-bonding interactions. The Hirshfeld surface analysis of the crystal structure indicated that the most important contributions for the crystal packing were from H…H (30.3%), O…H/H…O (23.1%), V…O/O…V (8.7%), H…C/C…H (8.4%), N…C/C…N (7.8%) and O…O (4.1%) interactions. Interestingly, this compound showed highly anti-proliferative effect on the melanoma cell line (IGR39) with an IC50 value of 7 µM, without being cytotoxic. However, it displayed cytotoxic effect on triple negative breast cancer cells (MDA-MB-231) with IC50 values of 18.7 and 6 µM, after 24 h and 72 h treatments, respectively. These results contributed to better understand the structure-function relationship of the decavanadate compounds, in order to develop the next generation antitumor drugs, targeting specific cancer cells.